Peter J. Fraser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peter J. Fraser has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Ricky W. Johnstone
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
22 shared publications - Belinda Maher
Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
21 shared publications - Daniella Brasacchio
Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
21 shared publications - Jake Shortt
Monash University
21 shared publications - Leonie A. Cluse
Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
21 shared publications - Lev M. Kats
Peter MacCallum Cancer Centre, Melbourne, Australia
21 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Correlation of DepMap gene effect dependency score and percentage inhibition by VPR8 for the targets that showed >50% inhibition by VPR8. (B-C) RNAseq of JJN3 cells treated with B32B3 or VPR8 for 6 and 24h. (B) Volcano plot and number of differentially expressed genes (p < 0.01 & |logFC| > 0.5). (C) Heatmap of the union of VPR8 and B32B3 differentially expressed genes (DEGs) at 24 hr. (D-E) Number of differential phosphopeptides and proteins. (F) Heatmap of the proteins that are differentially expressed following 24hr VPR8 treatment.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Correlation of DepMap gene effect dependency score and percentage inhibition by VPR8 for the targets that showed >50% inhibition by VPR8. (B-C) RNAseq of JJN3 cells treated with B32B3 or VPR8 for 6 and 24h. (B) Volcano plot and number of differentially expressed genes (p < 0.01 & |logFC| > 0.5). (C) Heatmap of the union of VPR8 and B32B3 differentially expressed genes (DEGs) at 24 hr. (D-E) Number of differential phosphopeptides and proteins. (F) Heatmap of the proteins that are differentially expressed following 24hr VPR8 treatment.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with 1µM VPR8, displaying microtubule disruption and abnormal spindle formation. Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with 1µM VPR8, displaying microtubule disruption and abnormal spindle formation. Time (hr:min).
- Open Access
- 2 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100214
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma
- 2 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100214
Open AccessEnhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cell (indicated with light blue arrowhead) treated with DMSO, undergoing mitosis and cytokinesis. Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min)
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cell (indicated with light blue arrowhead) treated with DMSO, undergoing mitosis and cytokinesis. Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min)
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity